Introduction {#Sec1}
============

A major obstacle to the development of effective glioma therapeutics and imaging agents is that until very recently, murine models of glioma have not accurately recapitulated the heterogeneous and highly invasive nature of this lethal form of brain cancer \[[@CR1]--[@CR3]\]. Even though these models have limitations, they are widely used, and in longitudinal studies the tumors are usually tracked with quantitative fluorescence/bioluminescence imaging \[[@CR4], [@CR5]\]. Optical methods do not capture tumor morphology, but magnetic resonance imaging (MRI), which has been applied to xenograft models, is able to acquire detailed images of implanted tumors \[[@CR6], [@CR7]\]. There is a clear need for the combination of a truly representative glioma model, and the imaging detail provided by MRI, to generate more relevant assessments of candidate glioma therapeutics \[[@CR1]\]. Accordingly we sought to characterize the MRI features of a comparatively new murine model of glioma \[[@CR8]\]. This model is an orthotopic xenograft using human glioma stem cells (hTSCs) that has been recently described- it closely reproduces the biology of glioma in humans, and it is straightforward to implement \[[@CR8]\]. Our goal was to analyze conventional MRIs acquired longitudinally over several weeks to fully chronicle the behavior of the hTSC model, and thus create a glioma model/MRI---based test platform.

A rapidly evolving focus in glioma research is to identify agents that can suppress the invasive character of the disease \[[@CR9]\]. Widely used glioma models such as the U87, U251 and U373 human glioma cell lines implanted in the frontal cortex of mice, while very useful for some types of studies, grow mainly by enlargement of the tumor mass, and do not exhibit infiltrative and invasive growth \[[@CR1], [@CR10]--[@CR13]\]. While the recognized need for new glioma models has elicited the creation of genetic models which effectively recapitulate the features of patient tumors, these models create tumors in a variable time scale and only in a small proportion of the animals and are thus not entirely practical \[[@CR1], [@CR6], [@CR7], [@CR14]\]. Another strategy for establishing in vivo test platforms is to transplant murine glioma neurospheres into the brains of immunocompromised (SCID) mice \[[@CR15]\]. A recent variant of this approach utilizes human tumor stem cells (hTSC) implanted into the mouse brain, and has been shown to quite closely recapitulate the genotypic and phenotypic features of the original human tumor \[[@CR13]\]. There are several reasons why such models should be characterized in terms of their MRI features. First, MRI is the modality of choice to routinely monitor tumor progress in glioma patients, so in mice the tumor response to a specific therapy can most directly be related to what might be observed in patients by using the same imaging modality \[[@CR6]\]. In addition, MRI allows imaging of unlabeled cells, while optical methods require the tumor cells to stably express a fluorophore protein which might bias tumor cell behavior \[[@CR16]\]. Finally, MRI is a non-invasive and accurate method by which tumor growth and volume can be determined in live mice.

Our proposed test platform is intended to facilitate MR brain imaging and contrast agent development. Although robust contrast enhancement is the clinical MRI marker of high tumor grade, up to 45% of non-enhancing lesions prove to have high grade histology at biopsy, and a small but significant number (4%) of gliomas lack contrast enhancement \[[@CR17]--[@CR23]\]. Equally significantly, the correlation between histopathologic tumor grade and time to progression and survival is imperfect \[[@CR21]--[@CR23]\]. A large number of advanced techniques are under study in this context. Improvement in the reproducibility and sensitivity of routine contrast enhanced imaging might be facilitated using a cost-effective, practical, and relevant xenograft model.

In view of the foregoing, we sought to determine if the mouse hTSC model displayed the salient MRI findings of human glioma, which include obvious contrast enhancement and a surrounding irregular infiltrative morphology along the interface with the adjacent white matter \[[@CR17]--[@CR19]\]. Accordingly we characterized the MR imaging properties of the hTSC and U87 models in vivo using conventional MRI techniques. We applied these methods serially over several weeks to chronicle the progression of glioma as would be done during therapeutic agent development. The results illustrate that the hTSC---MRI mouse model recapitulates the MR findings diagnostic of human glioma and is a suitable platform for preclinical testing of new therapeutic and imaging approaches.

Materials and methods {#Sec2}
=====================

Mouse xenograft models {#Sec3}
----------------------

### Animal subjects {#Sec4}

SCID mice of either sex and weighing between 20 and 25 g were housed in micro-isolator cages with autoclaved bedding, and supplied with autoclaved food and water. Proper procedures for SCID mouse handling, husbandry and attention to comfort and clinical condition after tumor implantation were strictly observed. The entire, detailed study protocol was reviewed and approved by the institutional review committee for animal research \[Brigham and Women's Hospital (BWH) IACUC\].

### Cell lines {#Sec5}

The U87 cell line was grown as an adherent culture in media containing serum. Primary high grade human glioma (glioblastoma) tissue was acquired surgically, dissociated, and cultured in stem cell selection media to form tumorspheres.

### Patient derived glioma cells {#Sec6}

The tumor tissue was freshly acquired during surgery performed before the patient underwent any chemo- or radiotherapy. The patient had a typically contrast enhancing mass upon MRI examination prior to surgery. Pathology examination of the tissue confirmed that the tumor was a primary glioblastoma. Following acquisition the tumor tissue was immediately dissociated in artificial CSF. The glioblastoma cells were plated into dishes containing stem cell isolation media and after 5 days the fully formed tumorspheres were dissociated and the cells implanted into mice \[[@CR8]\].

### Intracranial implantation {#Sec7}

Aseptic surgical methods were followed in accordance with BWH guidelines. The U87 cultures and the tumorspheres (hTSC) were dissociated, counted, and concentrated into a compact suspension (1--2 μl). The mice were anesthetized with ketamine/xylazine, the head was swabbed with Betadine^®^, and body temperature was maintained with a circulating water pad. Tumor cell suspensions were injected stereotaxically into the right frontal cortex at 1 μl/min using a 5 μl Hamilton syringe \[[@CR21]\]. The syringe was left in place for 5 min before retraction to prevent reflux of the injected material. One group of mice (*n* = 7) was injected with approximately 1,500 hTSCs. A second group (*n* = 6) was implanted with 10,000 U87 cells; a relatively larger number of these cells was needed in order to establish viable tumors which approximated the size of the hTSC gliomas in a similar time frame.

Longitudinal imaging studies {#Sec8}
----------------------------

### Imaging schedule {#Sec9}

MRI imaging of U87 and hTSC tumors was performed every week in U87 mice starting at week 3 and every 2 weeks in hTSC mice starting at week 4. This was the imaging schedule that we found best balanced tumor viability with growth rates, which varied with tumor size at various timepoints. The hTSC tumor was not detectable by imaging until week 4 and it grew rapidly thereafter. The growth rate between U87 tumors was relatively uniform between subjects, and the mice were sacrificed after the second scan (week 2), while the hTSC mice were imaged between 2 and 5 times (weeks 2--5) before sacrifice, reflecting the greater heterogeneity of hTSC tumors in terms of growth rate.

### MR imaging protocol {#Sec10}

The mice were anesthetized with a mixture of 1.5% isofluorane and 95% oxygen throughout imaging. MRI was performed on a 4.7T horizontal bore system interfaced with a commercial scanner console (Bruker BioSpin Corporation, MA) using a homogenous quadrature birdcage head coil. Coronal T2-weighted images (T2WI) (TR/TE~eff~ = 2,000/72 ms) were acquired with a 2D fast spin echo sequence at 1 mm slice thickness with 80 μm × 130 μm in-plane resolution. Magnevist^Tm^ Gd-DTPA was injected intraperitoneally at 0.7 mmol/kg and coronal T1-weighted images (T1WI) (TR/TE~eff~ = 417/24.5 ms) were acquired once before and twice after contrast injection. Post-contrast imaging was performed at 12 min after injection, which based on our prior experience ensured optimal contrast enhancement (data not shown).

Data analysis {#Sec11}
-------------

### MR tumor morphology {#Sec12}

A trained, blinded observer who was unaware of the origins of each MR acquisition, evaluated the MR volumes in terms of how well circumscribed the tumor boundary appeared and in terms of the presence or absence of an irregular infiltrative zone.

### Histopathological correlation {#Sec13}

Histology was performed to confirm the MR findings. The mouse brains (*n* = 13: *n* = 6 U87, *n* = 7 hTSC) were removed and sliced to 1 mm thickness, matching the MR slice thickness. The 1 mm slices were fixed in formalin, sectioned to 5 μm, and stained with hematoxylin and eosin (H&E). The H&E sections were examined by a pathologist, and cellular atypia, anaplasia, mitotic activity, microvascular proliferation, infiltration and tumor border topography, and necrosis were observed, quantified and tabulated. The tabulated data was then compared to the findings for the corresponding MR slice acquisitions.

### MR contrast enhancement measurements {#Sec14}

Brain enhancement represents a measure of tumor microvascular permeability, and relates to how therapeutic agents might be distributed within a tumor and whether contrast agents can highlight a small tumor. We used the usual normalization method in which a ratio of contrast enhancement is determined by comparing tumor tissue to contralateral normal brain. We also calculated a ratio of enhancement comparing the tumor with cervical skeletal muscle (sternocleidomastoid). This was performed to provide a check for the tumor versus normal brain ratio, since it is possible that inaccuracies might arise from altered permeability in the reference white matter due to tumor infiltration and edema.

The tumor to contralateral white matter ratio (TWR) and the tumor-muscle enhancement ratio (TMR) were the mean signal intensity of the enhanced tumor divided by mean signal intensity of white matter and cervical muscle, respectively, at the 12 min post-contrast T1WI. Maximum enhanced regions of interest (ROI) were selected manually on the pre- and post-contrast images by a blinded observer who was not aware of the identities of the scans. The T1 and T2 acquisitions for each subject were cross-referenced to ensure proper ROI location.

Results {#Sec15}
=======

Tumor morphology imaged by MRI {#Sec16}
------------------------------

All the U87 tumors (*n* = 6) had a well-demarcated margin (Fig. [1](#Fig1){ref-type="fig"}), and no central necrosis was observed. They had relatively uniform hyperintensity compared to surrounding brain parenchyma on T2WI, and all displayed clearly visible contrast enhancement that was quite uniform. Hydrocephalus often develops with U87 tumors in mice, and was observed in four of the animals. However, no necrotic regions were detected with the U87 tumors. In contrast the hTSC tumors (*n* = 7) exhibited an irregular morphology, and by 6 weeks all the T2WI images displayed variably enhancement regions compared with the uniformity of enhancement seen in U87 tumors. Intratumoral necrosis was not evident on the early scans, but was clearly visible in four mice between 6 and 10 weeks after hTSC implantation. Hydrocephalus due to blockage of the brain ventricles appeared in all hTSC animals by 8 weeks.Fig. 1MRI features of 2 week U87 and hTSC tumors. **a** U87 tumor T2W acquisition. Note the smooth outline of the U87 tumor (*arrow*). **b** Shows the post-contrast T1W image for the same tumor/slice as in panel (**a**). The tumor can be seen to be clearly enhancing. **c** T2W image slice of hTSC tumor. Note the irregular tumor outline (*arrows*), invasion of ventricular areas, non uniform shading, and an invasive profile on the left of the main mass. The expanded view of the tumor indicates the irregular and invasive nature of the hTSC tumor. **d** Post-contrast T1W image slice for same tumor as in panel (**c**). The hTSC tumor displays minimal contrast enhancement

Histopathological correlation with MRI morphology {#Sec17}
-------------------------------------------------

There was no significant difference between U87 and hTSC tumors in terms of cellular atypia, anaplasia, mitotic activity, and microscopic necrosis. This suggests that failure to detect necrosis in the U87 tumors with MRI may have been due to limitations in MR sensitivity. Notwithstanding, the hTSC tumors were much more irregular that U87 tumors in terms of their overall morphology (Fig. [2](#Fig2){ref-type="fig"}). The hTSC tumors showed a very pronounced cellular infiltration of normal brain parenchyma, and were aggressively invasive. Subventricular zone infiltration was present in 6 of 7 hTSC tumors, compared to 0 of 6 of the U87 tumors (Fig. [2](#Fig2){ref-type="fig"}a--c). The hTSC tumors very much mimicked human glioma, exhibiting distinct, irregular masses of growth with infiltrative components present to varying degrees in different mice and at different time points.Fig. 2Histology of U87 and hTSC tumors. All images H&E, *t* tumor, *b* normal brain. **a** U87 tumor appears rounded (darker staining regions) with distinct boundaries. **b** U87 tumor image clearly shows a typical rounded and cleanly demarcated tumor profile. **c** Closer view of U87 tumor shows very little infiltration of adjacent normal brain. **d** Overview of hTSC tumor showing highly scattered and invasive tumor with irregular outline (tumor includes darker staining areas) **e** hTSC tumor invasion into subventricular zone along ventricles. **f** hTSC tumor cell infiltrate into brain with no clear brain-tumor boundary

TMR and TWR contrast enhancement {#Sec18}
--------------------------------

In the U87 tumors, which consistently contrast enhanced, the final mean TWR was 1.67 ± 0.23 with variance of 13.9, as represented by the maximally enhanced region (Fig. [1](#Fig1){ref-type="fig"}). Mean TMR using the same tumor regions was 1.11 ± 0.06 with variance of 5.6. Both normalization methods showed similar trends in terms of enhancement, but the TWR was more variable, possibly due to the effects of white matter edema or variations in blood brain barrier permeability and contrast diffusion.

Contrast enhancement {#Sec19}
--------------------

The hTSC tumors did enhance in 11 of 18 time point measurements (*n* = 7 mice), but a significant proportion showed very little or no enhancement at early times. The range for enhancing regions was 8.5--233%. During the development of the hTSC tumors, there was an increase of TWR and TMR across all animals (*n* = 7). A representative example is shown in Fig. [3](#Fig3){ref-type="fig"}a showing an abrupt change of vascular permeability. The permeability of all hTSC tumors increased during the course of tumor development and eventually did reach that of U87 tumors (Fig. [4](#Fig4){ref-type="fig"}a--c). hTSC tumors exhibited greater variability in microvascular permeability within tumors and across animals than did the U87 tumor group.Fig. 3Longitudinal imaging of hTSC tumors. Four weeks after implantation the hTSC tumors were hyperintense on T2WI (**a**) and showed post-contrast enhancement in T1WI (**b**). From the 4th week to 6th week post-inoculation, the tumor grew from 4.4 mm diameter (**c**--**d**) to 6.8 mm diameter as shown in this T2WI (**e**--**f**). Even at 6 weeks the tumor did not enhance as indicated by the post-contrast T1WI (**d**). By the 8th week the tumor had enlarged significantly as shown by the T2WI acquisition (**e**), the mouse evinced signs of hydrocephalus, and the post-contrast T1WI image was strongly enhancedFig. 4Contrast enhancement over time in U87 versus hTSC tumors. **a** MR image slices acquired for a U87 tumor, at two timepoints separated by 14 days. The upper panels marked 'start' are the first pair of T2W and T1W post contrast images. For the U87 tumor the initial and final 'end' acquisitions show the same degree of strong enhancement, even though they differ in size. Note the smooth outline of the tumor at 14 days. **b** MR images, 14 days apart, acquired for an hTSC tumor. The initial acquisition shows little or no enhancement, while the 14 day acquisition has strong enhancement. Note the irregular outline of the tumor in the contrast enhanced image at the second timepoint. **c** Quantitative representation of contrast enhancement for U87 tumors, for hTSC tumors at beginning of 2-week period 'start' and at conclusion of 2-week period 'end'. The U87 contrast versus hTSC at start of period differed significantly (*P* = 0.0001; parametric, unpaired *T*-test), and the start hTSC contrast differed from that at the end (*P* = 0.0002). The mean (line *x*), the range (*box*) and the standard deviation (*bars*) are indicated for each group

MR detection of subtle microvascular effects in hTSC tumors {#Sec20}
-----------------------------------------------------------

Our data revealed that minimally enhancing hTSC tumor did in fact show subtle evidence of increased microvascular permeability during the beginning of 2-week period. Figure [5](#Fig5){ref-type="fig"} shows the MRI characteristics of a representative example from the minimally enhancing glioma. The tumor was very large and had a long T2 (Fig. [5](#Fig5){ref-type="fig"}a), but relatively modest enhancement on post-Gadolinium T1WI (Fig. [5](#Fig5){ref-type="fig"}b). The invasive tumor tissue (T2WI, Fig. [5](#Fig5){ref-type="fig"}c) indicated by the thin white arrows showed very mild enhancement in Fig. [5](#Fig5){ref-type="fig"}d. Oval ROIs were drawn on the post-contrast T1WI depicting the location of the cervical muscle reference sites in Fig. [5](#Fig5){ref-type="fig"}d, guided by the T2W image of 5d. Interestingly, even though the invasive tumor tissue was subtly enhanced, Fig. [5](#Fig5){ref-type="fig"}d shows that on the corresponding post-contrast T1WI, it was hypointense compared to muscle. In contrast the representative MRI of a U87 tumor in Fig. [5](#Fig5){ref-type="fig"}g shows that these tumors are highly enhancing compared to muscle on the delayed post-Gadolinium T1WI. These data reveal that microvascular permeability patterns and changes can be expected to be quite different using the U87 model versus the more physiologically relevant hTSC tumor model.Fig. 5MR detection of subtle microvascular effects in hTSC tumors. **a** T2W image of a large hTSC tumor. **b** Post-contrast T1W image of the same slice; tumor was very large but the contrast enhancement and thus vascular permeability were relatively low. **c** T2W image used to define cervical muscle ROIs and tumor invasion (*thin arrows*; *thick arrow* shows normal tissue). **d** invasive tumor tissue showing only mild enhancement. Even though the invasive tissue showed subtle enhancement, it was hypointense compared with the cervical muscle reference loci. **e** T2W image of cervical muscle in a U87 tumor bearing mouse. This image was used to define reference ROIs. **f** Is the T1W post-contrast image of the same slice as the cervical ROI T2W image and shows enhancement in the muscle tissue. **g** Shows the post-contrast T1W image of the U87 tumor which is clearly hyperintense compared to the cervical muscle and surrounding brain

Discussion {#Sec21}
==========

We report the MR imaging characteristics of a new human stem cell (hTSC) xenograft model \[[@CR9], [@CR13], [@CR15]\]. This model was recently developed in response to the generally perceived need for animal models that reproduce the angiogenic and invasive natural history of human glioma \[[@CR1], [@CR13], [@CR15]\]. MR imaging is indispensable for managing glioma patients, and MRI has been increasingly used for the assessment of drug effects in animal models of brain cancer \[[@CR1], [@CR17]--[@CR19]\]. Therefore, we sought to complete the hTSC model by characterizing its MR features relative to well-established MR findings in human glioma, and to the widely used U87 glioma model. Conventional MR examinations validated histologically, revealed that hTSC tumors mimicked the MR profile typically observed with glioma patients. The MRIs revealed evidence of angiogenesis and/or increased tumor vessel permeability via longitudinally developing, irregularly distributed contrast enhancement, tumor invasiveness, and heterogeneity within and between tumors. As expected, the well circumscribed, spherical U87 MR profile and uniform contrast enhancement did not resemble the MR appearance of patient gliomas.

Previous investigations of quantitative permeability imaging in various tumor models has established that tumor enhancement is produced by a combination of: (1) increase in capillary blood volume due to an increase in blood flow within existing brain capillaries, (2) impairment of the blood--brain barrier (BBB) in native capillaries due to diffusible paracrine factors released by the tumor or host immune response, and (3) the formation of new leaky tumor microvessels (angiogenesis), which is the main effect \[[@CR24], [@CR25]\]. Thus while Gd detection represents an admixture of effects, escalating Gd enhancement over time is one of the best established clinical surrogate imaging markers of angiogenesis \[[@CR24], [@CR25]\]. Low grade human gliomas initially show little contrast enhancement, and then as they progress to higher grade tumors they begin to express strong contrast enhancement \[[@CR26]--[@CR30]\]. On the other hand, high grade gliomas, viz., the glioblastomas, exhibit vivid contrast enhancement upon first presentation, but this is not always the case, as some glioblastomas do not or minimally enhance initially \[[@CR31], [@CR32]\]. Moreover patients are MR imaged after they are symptomatic, so it is possible that early tumors, if they were to be MR imaged, might not enhance until they have progressed sufficiently to cause symptoms. In any case the finding that not all the hTSC tumors enhanced initially, that they all enhanced at 2 weeks, and that they exhibited a heterogeneous and irregular morphology suggests that this model mimics the human disease reasonably well.

Since the hTSC mouse model exhibits a progression from minimal enhancement to full enhancement, it may be an attractive translational test platform for the application of advanced imaging methods to define the temporal evolution of abnormal permeability in infiltrative progressive glioma. The dynamics and kinetics of tumor and brain delivery of therapeutic and contrast agents is considerably influenced by variations in vascular permeability, and based on our results the U87 and hTSC tumors can be expected to behave differently from each other in this regard over at least the first few weeks after implantation.

A limitation of the hTSC model is that it involves the implantation of *human* glioma cells into an athymic *nu/nu* or *SCID* mice. These murine models are immunocompromised, and it has been demonstrated that T cells do occur within gliomas and contribute to their natural history \[[@CR33]\].

The abrupt transformation from low enhancement to high enhancement in only the hTSC model, documents the sensitivity range of MRI in this model. This event is thought to result from the release of angiogenic factors and matrix metalloproteinases, and in humans heralds the onset of an angiogenic, aggressive glioma phenotype \[[@CR8], [@CR28], [@CR30]\]. Future work on this topic will require a comprehensive study in which the tumors are staged, and vascular permeability and density around the tumor are characterized using MR functional and histological approaches. This is beyond the scope of the present study, but a further systematic examination of the possible relationship between suddenly increased MR contrast enhancement in hTSC tumors and the angiogenesis will be the subject of a future research.
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